Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.40 |
| ▸ | HTR2B | P41595 | 10/20 | 0.40 |
| ▸ | HTR2A | P28223 | 7/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31330263 | 1.00 | HTR2C (0.40) | HTR2CHTR2BHTR2AP2RX7TACR1 | |
| SCHEMBL4471624 | 1.00 | HTR2C (0.40) | HTR2CHTR2BHTR2AP2RX7TACR1 | |
| SCHEMBL4467750 | 0.90 | HTR2C (0.40) | HTR2CHTR2BHTR2AP2RX7TACR1 | |
| SCHEMBL4467749 | 0.90 | HTR2C (0.40) | HTR2CHTR2BHTR2AP2RX7TACR1 | |
| SCHEMBL4465382 | 0.90 | RORC (0.42) | HTR2CHTR2BHTR2AP2RX7TACR1 | |
| SCHEMBL4467242 | 0.89 | HTR2C (0.43) | HTR2CHTR2BHTR2AP2RX7CACNA1S | |
| SCHEMBL4478197 | 0.88 | HTR2C (0.43) | HTR2CHTR2BHTR2AP2RX7TACR1 | |
| SCHEMBL4478192 | 0.88 | HTR2C (0.43) | HTR2CHTR2BHTR2AP2RX7TACR1 | |
| SCHEMBL4467969 | 0.86 | HTR2C (0.44) | HTR2CHTR2BHTR2AP2RX7TACR1 | |
| SCHEMBL4467971 | 0.86 | HTR2C (0.44) | HTR2CHTR2BHTR2AP2RX7TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572805-B2 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | HTR2B, OPRD1, HTR1B | HTR2C 17/4885HTR2B 1/4885HTR2A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.